MedTrace Logo

Serotonin/Dopamine Antagonism of Cocaine Effect: 2 - 2

NCT00000310 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2017-01-16

No results posted yet for this study

Summary

The purpose of this study is to evaluate use of risperidone with cocaine abusers. Study measures incorporate an appropriate integration of behavioral and neurobiological indices.

Conditions

  • Cocaine-Related Disorders

Interventions

DRUG

Risperidone

Sponsors & Collaborators

  • VA Boston Healthcare System

    collaborator FED

  • National Institute on Drug Abuse (NIDA)

    lead NIH

Principal Investigators

  • Lawrence Price, M.D. · Brown University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
1996-01-31
Primary Completion
1996-03-31
Completion
1996-03-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00000310 on ClinicalTrials.gov